IP Library › Granted Patent US 12,233,093
Granted Patent B2
US 12,233,093 · App. 17/867,321 · Granted Feb 25, 2025

Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling

Inventors: Judith A. Shizuru (Palo Alto, CA); Irving L. Weissman (Stanford, CA); Kipp Andrew Weiskopf (Sudbury, MA); Aaron Michael Ring (New Haven, CT); Akanksha Chhabra (San Francisco, CA); Peter Schnorr (Sudbury, MA)
Assignee: The Board of Trustees of the Leland Stanford Junior University
A61K35/28A61K38/1709A61K38/1774A61K38/1793A61K39/3955A61K45/06C07K16/2803C07K16/2878C07K16/2896A61K2039/505A61K2039/507C07K2317/74C07K2317/75C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,233,093
App. No.
17/867,321
Granted
Feb 25, 2025
Kind
B2
Abstract

The present invention provides a clinically applicable method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring radiotherapy or chemotherapy, and without development of GVHD or graft rejection. Aspects of the present invention are based on the discovery that the depletion of the endogenous stem cell niche facilitates efficient engraftment of stem cells into that niche. In particular, the present invention combines the use of selective ablation of endogenous stem cells with a combination of antibodies specific for CD117, and agents that modulate immunoregulatory signaling pathways, e.g. agonists of immune costimulatory molecules, in combination with the administration to the recipient of exogenous stem cells, resulting in efficient, long-term engraftment, even in immunocompetent recipients.

Claims (19)

1. A method of hematopoietic stem cell engraftment in a mammal, the method comprising:

contacting said mammal concomitantly with (i) a monoclonal antibody specific for CD117 at a dose of from 50 μg/kg body weight to 50 mg/kg body weight; and (ii) an agent that blocks interaction between CD47 and SIRPα, wherein the agent is selected from an anti-CD47 antibody, an anti-SIRPα antibody, a soluble SIRPα polypeptide or a fusion protein comprising a SIRPα polypeptide at a dose of from 50 μg/kg body weight to 100 mg/kg body weight; wherein the combination of doses is effective in ablating hematopoietic stem cells from bone marrow of said mammal; and

introducing exogenous hematopoietic stem cells to said mammal, wherein the exogenous hematopoietic stem cells engraft to provide for long-term multilineage hematopoietic engraftment.

2. The method of claim 1 , wherein the monoclonal antibody specific for CD117 is administered at a dose from 500 μg/kg body weight to 25 mg/kg body weight.

3. The method of claim 2 , wherein the monoclonal antibody specific for CD117 is administered at a dose from 500 μg/kg mg/kg body weight to 10 mg/kg body weight.

4. The method of claim 3 , wherein the monoclonal antibody specific for CD117 is administered at a dose from 500 μg/kg mg/kg body weight to 5 mg/kg body weight.

5. The method of claim 1 , wherein the agent that blocks interaction between CD47 and SIRPα is administered at a dose from 5 mg/kg body weight to 50 mg/kg body weight.

6. The method of claim 5 , wherein the monoclonal antibody specific for CD117 is administered at a dose from 10 mg/kg mg/kg body weight to 50 mg/kg body weight.

7. The method of claim 1 wherein the agent that blocks interaction between CD47 and SIRPα comprises a soluble SIRPα polypeptide.

8. The method of claim 7 , wherein the soluble SIRPα polypeptide is a high affinity SIRPα variant.

9. The method of claim 8 , wherein the soluble SIRPα polypeptide is CV1.

10. The method of claim 1 wherein the agent that blocks interaction between CD47 and SIRPα is an anti-CD47 antibody.

11. The method of claim 1 , wherein the agent that blocks interaction between CD47 and SIRPα is an anti-SIRPα antibody.

12. The method according to claim 1 , wherein said mammal is a human.

13. The method of claim 1 , wherein the engraftment is performed in the absence of myeloablative conditioning.

14. The method of claim 1 , wherein the mammal is immunocompetent.

15. The method according to claim 1 , wherein said exogenous stem cells are allogeneic stem cells.

16. The method of claim 1 , wherein the exogenous stem cells are autologous.

17. The method of claim 1 , wherein said contacting is repeated at least twice.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2022
From: SHIZURU, JUDITH A.; WEISSMAN, IRVING L.; WEISKOPF, KIPP ANDREW; RING, AARON MICHAEL; CHHABRA, AKANKSHA; SCHNORR, PETER JOHN
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 060718/0379 →
Continuity (4)
Continuation 16526794 · Jul 30, 2019
Continuation 15504264
Provisional Application 62041989 · Aug 26, 2014
Related Publication 20220347224A1 · Nov 3, 2022
References Cited (49)
US 5686278A · Williams et al. · 1997 [cited by applicant]
US 10105451B2 · Leboulch et al. · 2018 [cited by applicant]
US 20090191202A1 · Jamieson et al. · 2009 [cited by applicant]
US 20100226927A1 · Weissman et al. · 2010 [cited by applicant]
US 20100239579A1 · Smith et al. · 2010 [cited by applicant]
WO WO2004002425 · 2004 [cited by applicant]
WO WO2008067115 · 2008 [cited by applicant]
WO WO2009091601 · 2009 [cited by applicant]
WO WO2011034969 · 2011 [cited by applicant]
WO WO2013056352 · 2013 [cited by applicant]
WO WO2013109752 · 2013 [cited by applicant]
WO WO2015138600 · 2015 [cited by applicant]
WO WO2016033201 · 2016 [cited by applicant]
WO WO2016205042 · 2016 [cited by applicant]
(2006) Chapter 2 of Regenerative Medicine, Department of Health and Human Services. [cited by applicant]
Ballas, (2002). “Sickle cell anaemia: progress in pathogenesis and treatment”, Drugs. 62(8):1143-72. [cited by applicant]
Bartkowiak & Curran, (2015). “4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity”, Front Oncol. 5:117. [cited by applicant]
Chhabra et al., (2014) “Successful Engraftment of Hematopoietic Stem Cells into Immunocompetent Recipients Using Only Anti-CD117 Antibody and CD47 Blockade As Conditioning.”, Blood. 124(21):241. [cited by applicant]
Chhabra et al., (2016) “Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy”, Science Translation Medicine, pp. 1-10, vol. 8 No. 351, American Association for the Advanceme… [cited by applicant]
Edris et al., (2013). “Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors”, Oncoimmunology, 2(6): e24452. [cited by applicant]
Farmakis et al., (2003). “Pathogenetic aspects of immune deficiency associated with beta-thalassemia”, Med Sci Monit. 9(1):RA19-22. [cited by applicant]
Grez et al., (2011). “Gene therapy of chronic granulomatous disease: the engraftment dilemma”, Mol Ther. 19(1):28-35. [cited by applicant]
Henig & Zuckerman, (2014)., “Hematopoietic stem cell transplantation—50 years of evolution and future perspectives” Rambam Maimonides Med J. 5(4): e0028. [cited by applicant]
Kohn et al., (2013). “Gene therapy through autologous transplantation of gene-modified hematopoietic stem cells” Bioi Blood Marrow Transplant. 19(1 Suppi):S64-9. [cited by applicant]
Kontermann, (2012). “Dual targeting strategies with bispecific antibodies”, MAbs. 4(2): 182-97. [cited by applicant]
Larochelle & Dunbar, (2013). “Hematopoietic stem cell gene therapy: assessing the relevance of preclinical models”, Semin Hematol. 50(2):101-30 (available in PMC Apr. 1, 2014). [cited by applicant]
Lennartsson & Ronnstrand, (2012). “Stem cell factor receptor/c-Kit: from basic science to clinical implications”, Phsyiol Rev. 92(4):1619-49. [cited by applicant]
Logan et al., (2012). “The road to purified hematopoietic stem cell transplants is paved with antibodies”, Curr Opin Immunol. 24(5): 640-648. [cited by applicant]
Murata et al., (2014). “The CD47-SIRPα signaling system: its physiological roles and therapeutic application”, J Biochem. 155(6):355-44. [cited by applicant]
Nickel et al. (2014) The ethics of a proposed study if hem Hematopoietic Stem Cell Transplantation for Children with “less severe” sickle cell disease. Blood, 124;(6) pp. 861-866. [cited by applicant]
Pai et al. (2014) Transplantation outcomes for severe Combined Immunodeficiency, 2000-2009, 31; 371(5) pp. 434-446. [cited by applicant]
Pang (2019) “Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice” Blood 133(19). [cited by applicant]
Peinemann & Labeit, (2014). “Autologous hematopoietic stem cell transplantation following high-dose chemotherapy for non-rhabdomyosarcoma soft tissue sarcomas: a Cochrane systematic review”, BMJ Open, 4(7): e005033. [cited by applicant]
Petersen, (2007). “Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative… [cited by applicant]
Raut et al. (2015) Improving Outcome of Aplastic with HLA-Matched Sibling Donor Hematopoietic Stem Cell Transplantation: An Experience of Gurat Cancer and Research Institute, 31(1); pp. 1-8. [cited by applicant]
Rozanov et al., (2015). “A humanized leucine zipper-TRAIL hybrid induces apoptosis of tumors both in vitro and in vivo”, PLoS One. 10(4): e0122980. [cited by applicant]
Schroeder & Cavacini, (2010), “Structure and function of immunoglobulins”, J Allergy Clin Immunol. 125(2): S41-S52. [cited by applicant]
Tavare (2014), “Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo”, PNAS 111(3): 1108-1113. [cited by applicant]
Valdez et al., (2009) “Infections in patients with aplastic anemia”, Semin Hematol. 46(3):269-76. [cited by applicant]
Viola-Villegas (2014), “Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives”, Molecular Pharmaceutics 11:3965 3973. [cited by applicant]
Weiskopf & Weissman, (2015). “Macrophages are critical effectors of antibody therapies for cancer”, MAbs. 7(2): 303-310. [cited by applicant]
Weiskopf et al., “Improving macrophage responses to therapeutic antibodies by molecular engineering of SIRP α variants” OncoImmunology, Sep. 2013, pp. e25773-1-e25773-3, vol. 2, No. 9, Landes Bioscience, Austin, TX. [cited by applicant]
Weiskopf et al., (2016)., “Myeloid Cell Origins, Differentiation, and Clinical Implications”, Microbiol Spectr.4(5): 10.1128/microbiolspec.MCHD-0031-2016. [cited by applicant]
Xue et al., (2010) “Antibody targeting KIT as pre-transplantation conditioning in immunocompetent mice” Blood. 116(24):5419-22. [cited by applicant]
Chhabra et al. (2014) “Successful Engraftment of Hematopoietic Stem Cells into Immunocompetent Recipients Using Only Anti-CD117 Antibody and CD47 Blockade As Conditioning.” [cited by applicant]
Petersen (2007) “Alloreactivity as therapeutic principle in the treatment of hematologic malignancies.” [cited by applicant]
Schroeder et al. (2010) “Structure and function of immunoglobulins.” [cited by applicant]
Grounds for the interlocutory decision in the Jan. 21, 2020, Opposition proceedings of EP 07871350.0. [cited by applicant]
Patentee's submission of Feb. 21, 2018 in the prosecution of EP 15762121.0. [cited by applicant]